Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary Objectives: 1. To examine the safety and tolerability of PF-04360365 in subjects with mild-to moderate AD dosed for 18 months and followed for a total of 24 months; 2. To characterize the pharmacokinetics of PF-04360365 following administration of multiple doses in subjects with mild-to-moderate AD.
Critère d'inclusion
- mild to moderate Alzheimer's Disease